Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Vermillion, Inc. (VRML) Posts Q4, FY Financial Results And Operational Achievements 0 comments
    Mar 27, 2012 2:43 PM | about stocks: VRML

    Vermillion, a leading molecular diagnostics company, today reported its financial and operational results for the fourth quarter and full-year ended December 31, 2011, reflecting significant revenue increases for both periods.

    Total revenues in the fourth quarter of 2011 increased 152 percent to $868,000 from $345,000 reported for the fourth quarter of 2010. Fourth-quarter revenues included $755,000 from product sales of OVA1 and $113,000 of license revenue related to certain milestones associated with the company's amended strategic alliance agreement with Quest Diagnostics.

    The company reported fourth quarter 2011 total operating expenses of $3.9 million, a decrease from $4.5 million reported in the same period a year ago.

    Net loss for the fourth quarter was $3.1 million, or $(0.21) per share, as compared to $4.0 million, or $(0.38) per share, in the same year-ago quarter.

    Total revenues for the full year 2011 increased 64 percent to $1.9 million from $1.2 million in 2010. Full-year revenues in 2011 included $1.5 million from product sales of OVA1 and $454,000 of license revenue.

    Total operating expenses increased in 2011 to $19.4 million from $15.7 million in 2010.

    Vermillion's net loss for 2011 was $17.8 million, or $(1.25) per share, as compared to $19.0 million, or $(1.83) per share, reported in 2010.

    As of December 31, 2011, the company's cash and cash equivalents totaled $22.5 million.

    Operational achievements include a 147-percent increase in test volume of the company's flagship diagnostic OVA1® for all of 2011. Test volume increased 40 percent year-over-year for the fourth quarter of 2011.

    In December, Vermillion purchased substantially all of the assets associated with the ovarian cancer diagnostics business of Correlogic Systems, which included more than 1,800 prospectively collected diagnostic samples from ovarian tumor studies, three biomarker-related pending U.S. patents, proprietary software, and other intellectual property. The company is using these assets to advance its ovarian cancer franchise, including the development of OVA2™, its next-generation ovarian cancer test.

    The company also strengthened its patent portfolio, receiving nine notices of allowance, including patents for breast cancer biomarkers, ovarian cancer, lung cancer, Alzheimer's disease, and five biomarker patents related to peripheral artery disease (PAD).

    In October, Vermillion released positive top-line data from a clinical study of the company's PAD development program.

    For more information visit www.vermillion.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: VRML
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.